Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Regeneron: Solid Q1 Creates Platform For Further Upside
PropThink • SNY, REGN • Tue, May 7, 10:26 ET
Is It Time To Give Up On Dendreon?
C.R. Jackson • DNDN • Tue, May 7, 09:09 ET
Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Scott Matusow • ABT, ARRY, OPK • Tue, May 7, 09:01 ET
Arena And Vivus Weaken On Poor Obesity Drug Prospects In Europe
Brian L. Wilson • VVUS, ARNA • Tue, May 7, 01:25 ET
How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market
Brian L. Wilson • REGN • Mon, May 6, 17:46 ET
Netupitant Results Could Roil Tesaro In May
Richard Pearson • GSK, MRK, OPK • Mon, May 6, 09:25 ET
Cadence Pharmaceuticals: Ofirmev Launch Is Strong; Resolution Of Patent Issues Could Be Soon
Smith On Stocks • CADX • Mon, May 6, 07:26 ET
AVEO: Here's Looking At You, FDA
Bond Wells • AVEO • Sat, May 4, 18:47 ET
The ODAC Postmortem: Lessons Learned Part 1, AVEO
PropThink • AVEO • Fri, May 3, 21:18 ET
Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
PropThink • DYAX, HALO, VPHM • Fri, May 3, 21:10 ET
China's H7N9 Bird Flu And Novavax
Trent MacDonald • NVAX • Fri, May 3, 17:22 ET
Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple
Logical Assessment • ECYT, MRK, ONVO.PK • Fri, May 3, 14:44 ET
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
PropThink • IMUC, ONCS.OB, AMGN • Fri, May 3, 12:15 ET
Was Arena Taken Down Too Far?
Spencer Osborne • ARNA • Fri, May 3, 03:00 ET
Arena Falls, Pulls Anti-Obesity Application In Europe
Spencer Osborne • VVUS, ARNA • Thu, May 2, 17:48 ET
Athersys Has Some Promise, But Controversy And Doubt Remain
Alberto Savrieno • GSK, OSIR, PFE • Thu, May 2, 16:06 ET
Aveo Gets Bad News On Tivozanib
Derek Lowe • AVEO • Thu, May 2, 14:21 ET
Watching Zalicus Like A Hawk
PropThink • ZLCS • Thu, May 2, 13:39 ET
EPO Pills: A Challenge For Amgen And Johnson & Johnson
Peter Geschek • AMGN • Thu, May 2, 12:36 ET
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • ATHX, CUR, STEM • Thu, May 2, 08:11 ET
Lpath: The Leader In Lipidomics
Bay Area Biotech • LPTN • Thu, May 2, 06:37 ET
IPO Preview: Insys Therapeutics
IPOdesktop • INSY • Thu, May 2, 00:21 ET
A Sweeter Deal On The Horizon For Prolor Biotech?
Stefan Bordonaro • OPK, PBTH • Wed, May 1, 17:46 ET
Swinging For The Fences With Advanced Cell Technology
Michael J. Ray • MRK, NVS, PFE • Wed, May 1, 14:07 ET
Celsion's A Fighter
Quoth the Raven • CLSN • Wed, May 1, 13:16 ET
ViroPharma's Maribavir: Rising Like Phoenix
Theodore Cohen • VPHM • Wed, May 1, 13:02 ET
With A New Institutional Investor On Board, Northwest Biotherapeutics Breaks The Curse
Andreas Spiro • IMUC, NWBO • Wed, May 1, 10:37 ET
OXiGENE's Oncology Drugs Have Run Their Course
Bay Area Biotech • OXGN • Wed, May 1, 10:33 ET
Hedge Funds Are Buying These 3 Biotech Small Caps Trading Below Lowest Target Price
Kapitall • BDSI, NVAX, QCOR • Wed, May 1, 10:12 ET
Vivus And Anti-Obesity Sector Benefit From New Insurance Deal
Spencer Osborne • ARNA, OREX, VVUS • Wed, May 1, 09:11 ET
BioLineRx Pipeline Returns To The Winner's Circle
Len Zehr • BLRX • Wed, May 1, 08:43 ET
Stem Cells: Invest At Your Own Peril
EnhydrisPECorp • ASTM, CUR, MBLTY.PK • Wed, May 1, 05:33 ET
Biogen Idec - Too High Too Fast?
William Meyers • BIIB • Tue, Apr 30, 17:00 ET
No News Becoming Bad News For Lexicon Pharmaceuticals
Stephen Simpson • BMY, PFE, MRK • Tue, Apr 30, 15:20 ET
Transition Therapeutics Still Undervalued: Good Trial Outcome Shifts Focus To Lilly Decision
PropThink • LLY, TTHI • Tue, Apr 30, 14:52 ET
Will The Latest PerkinElmer Agreement Help TrovaGene Tap Into A $22 Billion Market?
Free Bird • PKI, TROV • Tue, Apr 30, 14:23 ET
Trovagene 'Ups The Ante' With PerkinElmer Collaboration
VFC's Stock House • PKI, TROV • Tue, Apr 30, 13:08 ET
Questcor Pharmaceuticals In Play Ahead Of Earnings Release
Brian L. Wilson • QCOR • Mon, Apr 29, 12:39 ET
Raised Guidance And Resolved Manufacturing Issues Support Alexion Shares
PropThink • ALXN • Mon, Apr 29, 11:03 ET
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • ACAD, CLDX, GSK • Mon, Apr 29, 08:15 ET
Why I Think InVivo Is Under-Valued
Jason Napodano • NVIV.OB • Mon, Apr 29, 05:25 ET
The Compelling Science Behind Synergy
Veziris Ventures • IRWD, SGYP • Mon, Apr 29, 05:14 ET
Arena To Offer Quarterly Results - What Investors Need To Hear
Spencer Osborne • VVUS, ARNA • Mon, Apr 29, 01:47 ET
Vivus Gets Positive Development In Europe
Spencer Osborne • VVUS • Mon, Apr 29, 01:20 ET
High But Well-Managed Risk, This Company Is One To Watch Out For
Emerging Equities • BTX • Sun, Apr 28, 06:28 ET
Regenerative Medicine's Time Has Come
Stock Investor • ASTM, CUR, NBS • Sun, Apr 28, 01:34 ET
PerkinElmers' Collaboration: Testimony To The Strength Of Trovagene's Novel Technology Platform
Mars Report • PKI, TROV • Fri, Apr 26, 13:18 ET
Hedge Funds Are Buying These 2 Biotech Stocks
Equity Options Guru • ACAD, MDVN • Fri, Apr 26, 11:49 ET
My Number One Ranked Stock
Bill Gunderson • REGN • Fri, Apr 26, 04:18 ET
Arena Short Story Getting Interesting
Spencer Osborne • ARNA • Fri, Apr 26, 03:41 ET

First Page
Previous Page
51 - 100 of 4231
Next Page
Last Page